Bimetallic nano mixtures enable rapid ultrasensitive detection of high risk HPV for early cervical cancer diagnosis
Source abstract
Abstract
Background High-risk human papillomavirus (HPV) infection, particularly HPV16 and HPV18, is the primary etiological factor in cervical cancer development. The oncogenic potential of these viruses stems from the action of viral E6 and E7 oncoproteins, which drive malignant transformation by degrading tumor suppressor proteins p53 and pRb, disrupting cell cycle regulation, and inducing genomic instability [1, 2]. These mechanistic insights underscore the critical need for sensitive, rapid, and reliable diagnostic tools suitable for point-of-care settings to enable early detection and intervention. Methods We designed, synthesized, and evaluated bimetallic nano mixture-based lateral flow assays (LFAs) employing Au-Cu, Ag-Cu, and Ag-Au nano mixtures for detection of HPV16 L1 and HPV18 L1 capsid proteins. Nanoparticles were characterized by dynamic light scattering (DLS), zeta potential analysis, scanning electron microscopy (SEM), Fourier transform infrared (FTIR) spectroscopy, UV-Vis spectroscopy, and X-ray photoelectron spectroscopy (XPS) before and after functionalization with CTAB and monoclonal antibodies. Analytical performance including linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, precision, specificity, and stability was systematically validated. Clinical evaluation was conducted using 100 cervical samples, with performance parameters calculated against PCR as reference standard. Additional experiments were performed to assess early infection detection capability, correlation with E6/E7 oncoprotein expression, and specificity in the presence of p53 and pRb tumor suppressor proteins. Results Physicochemical characterization revealed successful antibody conjugation across all formulations, with predictable increases in hydrodynamic size (5-7 nm) and shifts toward less negative zeta potentials (-30 to -35 mV). Among monometallic systems, Au nanoparticles demonstrated the highest analytical sensitivity (LOD = 1 ng/mL), while Cu nanoparticles showed the poorest performance (LOD = 12 ng/mL). Remarkably, bimetallic nano mixtures dramatically outperformed monometallic counterparts, with Ag-Au nano mixtures achieving the lowest LOD (0.15 ng/mL), highest linearity (R2 = 0.998), and most rapid response time (10 min). Time-course experiments revealed that Ag-Au LFA detected infection as early as day 3 post-infection, 4 days before detection of integrated viral DNA. Among 20 PCR-positive clinical samples, 18 (90%) showed detectable E6/E7 oncoprotein expression, with strong correlations between LFA signal intensity and both E6 (r = 0.82) and E7 (r = 0.79) levels. No cross-reactivity was observed with p53, pRb, or E6/E7 oncoproteins. Clinical evaluation demonstrated that Ag-Au formulations achieved superior clinical performance (95% sensitivity, 91-92% specificity for both HPV targets), 96% positive predictive value (PPV), and 89-90% negative predictive value (NPV). Conclusion Bimetallic nano mixture-based LFAs, particularly the Ag-Au formulation, represent a highly sensitive, specific, and rapid point-of-care diagnostic platform for HPV detection. By enabling early identification of high-risk HPV infection-the critical initiating event in cervical carcinogenesis driven by E6/E7-mediated disruption of p53 and pRb tumor suppressor pathways-this platform addresses a crucial need in cervical cancer prevention.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Cervical Cancer and HPV Research · Biosensors and Analytical Detection · Advanced Biosensing Techniques and Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (29)
Show source-provided references
1. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048–56.10.1016/S1470-2045(10)70230-8 ↗
2. Cloidt M, Vivo S, Thelen A, Naavaal S. Role of oral health providers in supporting HPV-related cancer prevention in the dental setting. J Calif Dent Assoc. 2025;53(1):2460754.
3. Fernandes JV, de Medeiros Fernandes TAA. Human papillomavirus: biology and pathogenesis. In: Human Papillomavirus and Related Diseases - From Bench to Bedside - A Clinical Perspective. IntechOpen. 2012.
4. Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68(2):362–72.10.1128/MMBR.68.2.362-372.2004 ↗
5. Dyson N, Howley PM, Münger K, Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934–7.10.1126/science.2537532 ↗
6. Chellappan S, Kraus VB, Kroger B, Münger K, Howley PM, Phelps WC, et al. Adenovirus E1A, simian virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proc Natl Acad Sci USA. 1992;89(10):4549–53.10.1073/pnas.89.10.4549 ↗
7. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell. 1993;75(3):495–505.10.1016/0092-8674(93)90384-3 ↗
8. Kessis TD, Slebos RJ, Nelson WG, Kastan MB, Plunkett BS, Han SM, et al. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage. Proc Natl Acad Sci U S A. 1993;90(9):3988–92.10.1073/pnas.90.9.3988 ↗
9. Moody CA, Laimins LA. Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer. 2010;10(8):550–60.10.1038/nrc2886 ↗
10. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370(9590):890–907.10.1016/S0140-6736(07)61416-0 ↗
11. Ambretti S, Mirasoli M, Venturoli S, Zerbini M, Baraldini M, Musiani M, et al. High-throughput polymerase chain reaction chemiluminescent enzyme immunoassay for typing and quantifying human papillomavirus DNAs. Anal Biochem. 2004;332(2):349–57.10.1016/j.ab.2004.06.004 ↗
12. Piao JY, Park EH, Choi K, Quan B, Kang DH, Park PY, et al. A rapid and sensitive colorimetric assay for HPV DNA based on the retardation of avidin-induced aggregation of gold nanoparticles. Biosens Bioelectron. 2018;115:39–45.
13. Ardekani LS, Thulstrup PW. Gold nanoparticle-mediated lateral flow assays for detection of host antibodies and COVID-19 proteins. Nanomaterials (Basel). 2022;12(9):1456.10.3390/nano12091456 ↗
14. Chen X, Leng Y, Hao L, Duan H, Yuan J, Zhang W, et al. Tailoring noble metal nanoparticle designs to enable sensitive lateral flow immunoassay. Theranostics. 2022;12(2):574–602.10.7150/thno.67184 ↗
15. Sahu SR, Devi MM, Mukherjee P, Sen P, Biswas K. Optical property characterization of novel graphene-X (X= Ag, Au and Cu) nanoparticle hybrids. J Nanomater. 2013;2013(1):232409.10.1155/2013/232409 ↗
16. Baptista P, Pereira E, Eaton P, Doria G, Miranda A, Gomes I, et al. Gold nanoparticles for the development of clinical diagnosis methods. Anal Bioanal Chem. 2008;391(3):943–50.10.1007/s00216-007-1768-z ↗
17. Link S, Wang ZL, El-Sayed MA. Alloy formation of gold-silver nanoparticles and the dependence of the plasmon absorption on their composition. J Phys Chem B. 1999;103(18):3529–33.10.1021/jp990387w ↗
18. Mao JY, Li HW, Wei SC, Harroun SG, Lee MY, Lin HY, et al. DNA modulates the interaction of genetically engineered DNA-binding proteins and gold nanoparticles: diagnosis of high-risk HPV infection. ACS Appl Mater Interfaces. 2017;9(51):44307–15.10.1021/acsami.7b13873 ↗
19. Appidi T, Mudigunda SV, Kodandapani S, Rengan AK. Development of label-free gold nanoparticle based rapid colorimetric assay for clinical/point-of-care screening of cervical cancer. Nanoscale Adv. 2020;2(12):5737–45.10.1039/D0NA00686F ↗
20. Lee H, Hwang NR, Hwang SH, Cho Y. Magnetic nanowires for rapid and ultrasensitive isolation of DNA from cervical specimens for the detection of multiple human papillomaviruses genotypes. Biosens Bioelectron. 2016;86:864–70.10.1016/j.bios.2016.07.066 ↗
21. Cordeiro M, Ferreira Carlos F, Pedrosa P, Lopez A, Baptista PV. Gold nanoparticles for diagnostics: advances towards points of care. Diagnostics (Basel). 2016;6(4):43.10.3390/diagnostics6040043 ↗
22. Motl NE, Smith AF, DeSantisa CJ, Skrabalak SE. Engineering plasmonic metal colloids through composition and structural design. Chem Soc Rev. 2014;43(11):3823–34.10.1039/C3CS60347D ↗
23. Toshima N, Yonezawa T. Bimetallic nanoparticles—novel materials for chemical and physical applications. New J Chem. 1998;22(11):1179–201.10.1039/a805753b ↗
24. Chica CEN, Tobón LLA, Abella JJL, Piedrahita MPV, Acevedo DN, Bermúdez PC, et al. Nanoparticle-based colorimetric assays for early and rapid screening of the oncogenic HPV variants 16 and 18. Clin Chim Acta. 2025;568:120144.10.1016/j.cca.2025.120144 ↗
25. Gao H, Wang C, He Y, Wu Q, Li S, Zhang Y, et al. RotEx-LAMP-LFA: An integrated microfluidic platform for rapid and sensitive HPV mRNA detection. Adv Sci. 2025;12(8):2412345.
26. Barra M, Montenegro L, Tarrés M, Gabasa Y, D’Andrea L, Fàbrega MJ, et al. Multiplex LAMP-LFA for HPV16, HPV18, and HPV45 DNA detection: A single-tube four-target approach. Anal Biochem. 2024;695:115654.
27. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. Geneva: WHO; 2021.
28. Borse VB, Konwar AN, Srivastava R. Perspectives of characterization and bioconjugation of gold nanoparticles and their application in lateral flow immunosensing. Drug Deliv Transl Res. 2020;10(4):878–902.10.1007/s13346-020-00771-y ↗
29. Ozcan A. Mobile phones democratize and cultivate next-generation imaging, diagnostics and measurement tools. Lab Chip. 2014;14(17):3187–94.10.1039/C4LC00010B ↗